Ivabradine Accord

Ivabradine, the active ingredient in Ivabradine Accord, is a If channel inhibitor presented as a tablet for oral use. It lowers heart rate to treat chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients. GNH USA supplies Ivabradine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac sinus node to reduce heart rate, benefiting conditions where heart‑rate control improves outcomes. - Chronic stable angina pectoris: decreases the frequency of angina attacks by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves exercise capacity and reduces hospitalization by maintaining a lower resting heart rate.

Ivabradine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate below the intended target. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe visual impairment. - Hypotension not related to other agents. - Allergic skin reactions. - Hepatic enzyme elevations.

Before prescribing Ivabradine, clinicians should assess several safety factors. - Monitor heart rate: confirm resting HR > 50 bpm prior to initiation and during therapy. - Avoid in severe hepatic impairment: reduced metabolism may increase exposure. - Caution with concomitant CYP3A4 inhibitors: may raise plasma levels. - Discontinue if symptomatic bradycardia or atrial fibrillation occurs. - Store at room temperature: keep in the original container, protect from moisture and heat.

Ivabradine can interact with drugs that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase Ivabradine concentrations. - Other bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (diltiazem, verapamil): may require dose adjustment. - CYP3A4 inducers (rifampicin, carbamazepine): can lower efficacy. - Drugs that prolong QT interval: additive risk of arrhythmia.